Background: We studied the clinical efficacy and toxicity of a low-dose interferon-7 (IFN-7) regimen in patients with metastatic renal cell carcinoma (RCC). Methods: Eighteen unselected patients with metastatic RCC (median Karnofsky 80%; median sites of metastases = 2; 10 patients were pretreated with immuno-therapy) were included in this protocol. They were treated with IFN-7 at 150 μg s.c. once a week until tumor progression. Each treatment cycle consisted of 6 weeks of therapy on an outpatient basis followed by a pause of 2 weeks. Results: Toxicity was generally mild with low-grade fever predominating. Of 17 patients evaluable for response, one partial remission (5 months) was observed in a patient with pulmonary and mediastinal metastases and 4 further patients had stable disease (5, 7, 7 and 12 months). Four patients received IFN-α/IL-2 subsequent to treatment with IFN-7. Interestingly the patient who achieved a partial remission had a further partial response to IFN-α and IL-2 following relapse under therapy with IFN-7. Conclusion: Treatment with low-dose IFN-7 had limited clinical efficacy in our unselected patient group.

Keywords:
Interferon-γ, Renal cell cancer
This content is only available via PDF.
© 1993 S. Karger AG, Basel
1993
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.